IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

Mar 08, 2017

NEW YORK (GenomeWeb) — IntegraGen announced today that it has signed an agreement giving Laboratoire Cerba the right to develop a tumor expression test based on its microRNA biomarker miR-31-3p.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Featured White Papers

Compatibility of POLYVIEW IHC Detection Reagents and HIGHDEF IHC Chromogens with Automated IHC Slide Stainers

Sep

20

Featured Webinar

Latest Advances in Tumor Genomic Profiling for Challenging Samples

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep

21

Featured Webinar

Processing Challenging Tumor Samples via Automated Tissue Dissection and Extraction-Free Library Prep

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Main menu